HAX-1 Inhibitors
HAX-1 inhibitors comprise a diverse range of chemicals that intricately modulate HAX-1 activity, primarily through the regulation of apoptotic, pro-survival, and cell cycle pathways. These inhibitors serve as valuable tools for understanding the nuanced interactions of HAX-1 within cellular processes. One class of HAX-1 inhibitors includes Obatoclax, Gossypol, and ABT-263 (Navitoclax), which target the Bcl-2 family and disrupt mitochondrial apoptosis pathways. HAX-1, known for its involvement in anti-apoptotic mechanisms, interacts with Bcl-2 family members. The indirect inhibition of HAX-1 by these inhibitors emphasizes the significance of apoptotic regulators in modulating HAX-1 activity and provides a distinctive strategy for targeted inhibition through Bcl-2 family modulation. Another class involves Rocaglamide A, Embelin, and Apoptosis Activator 2, influencing translation initiation, XIAP, and caspase activation, respectively. These inhibitors showcase alternative mechanisms for indirect HAX-1 inhibition, illustrating the intricate regulatory network governing HAX-1 function and highlighting avenues for targeted interventions.
Furthermore, 3,3'-Diindolylmethane (DIM), YM155, and A-1210477 target NF-κB, survivin, and Bcl-xL, respectively, disrupting pro-survival signaling pathways. The indirect inhibition of HAX-1 through these regulators underscores the interplay between survival signaling and HAX-1 activity, offering avenues for targeted inhibition through the modulation of pro-survival pathways. GSK690693, GSK'872, and BI-2536 represent inhibitors targeting Akt, RIPK3, and PLK1, respectively, influencing pro-survival signaling, necroptotic pathways, and cell cycle progression. The indirect inhibition of HAX-1 through these diverse pathways highlights the multifaceted nature of HAX-1 regulation. In conclusion, HAX-1 inhibitors form a comprehensive collection of chemicals that intricately modulate HAX-1 activity through various pathways. These inhibitors offer valuable insights into the regulatory mechanisms governing HAX-1 function, emphasizing the interconnectedness of apoptotic, pro-survival, and cell cycle pathways in orchestrating cellular responses.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Obatoclax Mesylate | 803712-79-0 | sc-364221 sc-364221A | 5 mg 10 mg | $94.00 $138.00 | ||
Obatoclax, a Bcl-2 family inhibitor, indirectly inhibits HAX-1 by disrupting mitochondrial apoptosis pathways. As HAX-1 interacts with anti-apoptotic proteins, the inhibition of Bcl-2 family members by Obatoclax influences apoptotic signaling, leading to the indirect inhibition of HAX-1. This highlights the crosstalk between mitochondrial apoptosis regulation and HAX-1 activity, providing a potential avenue for targeted inhibition. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Rocaglamide, an eIF4A inhibitor, indirectly inhibits HAX-1 by disrupting translation initiation. HAX-1 is implicated in mRNA translation control, and the inhibition of eIF4A by Rocaglamide A interferes with this process, resulting in the indirect inhibition of HAX-1. This emphasizes the role of translation regulation in modulating HAX-1 activity and provides a unique mechanism for targeted inhibition. | ||||||
Embelin | 550-24-3 | sc-201555 sc-201555A | 10 mg 50 mg | $87.00 $332.00 | 5 | |
Embelin, an XIAP inhibitor, indirectly inhibits HAX-1 by influencing apoptotic pathways. XIAP interacts with HAX-1 in anti-apoptotic signaling, and the inhibition of XIAP by Embelin disrupts this interaction, leading to the indirect inhibition of HAX-1. This underscores the interconnectedness of apoptotic regulators and HAX-1 activity, offering a potential avenue for targeted inhibition through XIAP modulation. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $114.00 $225.00 | 12 | |
Gossypol, a Bcl-2 family inhibitor, indirectly inhibits HAX-1 by disrupting mitochondrial apoptosis pathways. Similar to Obatoclax, Gossypol influences apoptotic signaling by targeting Bcl-2 family members, indirectly inhibiting HAX-1 through interference with anti-apoptotic mechanisms. This further supports the interplay between mitochondrial apoptosis regulation and HAX-1 activity, providing an alternative approach for targeted inhibition. | ||||||
ABT 263 | 923564-51-6 | sc-207241 | 5 mg | $240.00 | 16 | |
ABT-263 (Navitoclax), a Bcl-2 family inhibitor, indirectly inhibits HAX-1 by disrupting mitochondrial apoptosis pathways. By targeting Bcl-2 family members, ABT-263 interferes with anti-apoptotic signaling, leading to the indirect inhibition of HAX-1. This underscores the importance of apoptotic regulators in modulating HAX-1 activity and provides a distinct strategy for targeted inhibition through Bcl-2 family modulation. | ||||||
3,3′-Diindolylmethane | 1968-05-4 | sc-204624 sc-204624A sc-204624B sc-204624C sc-204624D sc-204624E | 100 mg 500 mg 5 g 10 g 50 g 1 g | $36.00 $64.00 $87.00 $413.00 $668.00 $65.00 | 8 | |
3,3'-Diindolylmethane (DIM), an NF-κB inhibitor, indirectly inhibits HAX-1 by disrupting pro-survival signaling pathways. HAX-1 is implicated in NF-κB activation, and the inhibition of NF-κB by DIM interferes with this process, resulting in the indirect inhibition of HAX-1. This highlights the role of NF-κB signaling in modulating HAX-1 activity, providing a potential avenue for targeted inhibition through NF-κB pathway modulation. | ||||||
Apoptosis Activator 2 | 79183-19-0 | sc-202956 | 5 mg | $92.00 | 2 | |
Apoptosis Activator 2, a caspase activator, indirectly inhibits HAX-1 by promoting apoptosis. HAX-1 is involved in anti-apoptotic mechanisms, and the activation of caspases by Apoptosis Activator 2 induces apoptosis, leading to the indirect inhibition of HAX-1. This emphasizes the interconnectedness of apoptotic regulators and HAX-1 activity, offering a potential avenue for targeted inhibition through caspase activation. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693, an Akt kinase inhibitor, indirectly inhibits HAX-1 by disrupting pro-survival signaling pathways. HAX-1 is regulated by Akt-dependent phosphorylation, and the inhibition of Akt by GSK690693 interferes with this process, resulting in the indirect inhibition of HAX-1. This highlights the role of Akt signaling in modulating HAX-1 activity, providing a potential avenue for targeted inhibition through Akt pathway modulation. | ||||||
YM 155 | 781661-94-7 | sc-364661 sc-364661A | 5 mg 25 mg | $129.00 $497.00 | 3 | |
YM155, a survivin inhibitor, indirectly inhibits HAX-1 by disrupting pro-survival signaling pathways. Survivin interacts with HAX-1 in anti-apoptotic signaling, and the inhibition of survivin by YM155 disrupts this interaction, leading to the indirect inhibition of HAX-1. This underscores the interconnectedness of pro-survival regulators and HAX-1 activity, offering a potential avenue for targeted inhibition through survivin modulation. | ||||||
A-1210477 | 1668553-26-1 | sc-507474 | 5 mg | $195.00 | ||
A-1210477, a Bcl-xL inhibitor, indirectly inhibits HAX-1 by disrupting mitochondrial apoptosis pathways. Bcl-xL is involved in anti-apoptotic signaling, and the inhibition of Bcl-xL by A-1210477 interferes with this process, resulting in the indirect inhibition of HAX-1. This emphasizes the role of Bcl-xL and anti-apoptotic regulators in modulating HAX-1 activity, providing a distinct strategy for targeted inhibition through Bcl-xL modulation. | ||||||